Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. - Test2 - elhamkhani - TriplyDB

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

http://www.wikidata.org/entity/Q37587740

about

Current understanding of interactions between nanoparticles and the immune system Dynamic models of viral replication and latency Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage CD8 T cell persistence in treated HIV infection HIV and aging: emerging research issues Renal epithelial cells produce and spread HIV-1 via T-cell contact Visualization and quantification of simian immunodeficiency virus-infected cells using non-invasive molecular imaging.The Dynamics of T and B Cells in Lymph Node during Chronic HIV Infection: TFH and HIV, Unhappy Dance Partners?Changes in Follicular CD4+ T Helper Cells as a Marker for Evaluating Disease Progression in the Competition between HIV and Host Immunity Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research Impact of Chronic HIV/SIV Infection on T Follicular Helper Cell Subsets and Germinal Center Homeostasis Bioinformatics and HIV latency.The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials Optimal Treatment Strategies in the Context of 'Treatment for Prevention' against HIV-1 in Resource-Poor Settings Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals Residual Viremia in Treated HIV+ Individuals Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 Recent Insights into the HIV/AIDS Pandemic.A comparison of elasticities of viral levels to specific immune response mechanisms in human immunodeficiency virus infection.A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Human Immunodeficiency Virus Playing Hide-and-Seek: Understanding the TFH Cell Reservoir and Proposing Strategies to Overcome the Follicle Sanctuary Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Immunologic strategies for HIV-1 remission and eradication.A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4+ T cells as a Major Niche for HIV-1 Transcription in HIV-Infected Patients.No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection.Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies.Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells.Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.Progress toward curing HIV infections with hematopoietic stem cell transplantation.Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.Role of myeloid cells in HIV-1-host interplay.Eradicating HIV-1 infection: seeking to clear a persistent pathogen.Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia.

P2860

Q26345204-43D01CC1-13ED-4F5B-B7D2-E164D86D9044 Q26866136-38FDEF07-E429-452E-9965-C86883810601 Q27014077-50BD6CB2-27BC-4C54-9FBF-CE01CB31FEA0 Q27014768-67327B69-5A6E-43F0-A182-1F99033308DE Q27016011-DF457802-7C82-4F39-A18C-B54A8DE0200D Q27313558-9D801909-8A9F-4524-95BC-1B76E2764D72 Q27323244-841F3C38-D4A2-41D5-9DB5-3214A248F724 Q28067520-E7E680CB-7448-45C0-A074-2822337F8615 Q28075718-ADCDF853-8349-4C27-838C-4DF041CB3159 Q28077662-E498B96A-1EE2-4249-8D17-2FE5E86B466F Q28077701-285798A6-A8E9-4FE2-A9B3-4D87014FCEEB Q28081427-1020A363-E4B7-46C2-8809-D823786D562F Q28087336-A7C10630-1A49-4C49-BD17-FDFECA4A766C Q28547109-2B0670D9-AD1B-4F94-BACA-552FC9441FA0 Q28551803-DA4C1408-0D3B-4490-B870-3C4B79D96C18 Q28552126-EC7B59A0-BE3F-4B9B-A104-EFA60D4C1E3F Q28552729-702423DA-F2D4-4385-8B06-07EBD14D6C21 Q28552730-CFE7CCC8-327F-4B96-B936-4012EA21A72C Q28655602-0CE7AA5F-198B-4011-BBBD-FC549F06C976 Q30235024-36D9B5BD-A530-4F34-9FC2-96BF161590E1 Q30596957-9C1D7FFB-9F65-4FDB-98F8-04B0760ED0DC Q33728690-A6E1DA36-F0C2-4CDE-8C34-4BC4D271FB6F Q33742139-344F25D4-1737-450B-A438-436743064FFA Q33867299-EAB2C0B0-A22A-4B92-86EA-E7F35AB8CA99 Q33896523-204772C3-3E94-4BF8-BE0F-A8CFDEC16404 Q33911247-612AB479-CA7F-4035-8D7A-A6DA5A872455 Q34450075-336B7283-1B8B-425C-970E-9651E5898F73 Q34502840-5321F2AD-CB64-4BEA-B2E5-BCB740187F47 Q34593784-8A3F5D9B-B396-4B20-B0C4-F5F7FF2FAD8D Q34596417-A3F355F5-7CB8-46EC-A6FD-62AC2DACD70E Q34612385-D1ECC72B-BC08-4B1F-90C3-AA36D8578AE0 Q34669697-C82CDCEF-8CB8-4EC6-80F6-BA9248FDE7AD Q34869449-1E31B304-4542-4BC5-B83C-FC9766E481CB Q34974480-257B064E-C0D5-4521-90CB-7F2690CEE69C Q35147145-17488784-6D3C-417B-96AB-620291B74B50 Q35190018-B8473DD1-A740-4AC2-A429-B6D5962041B4 Q35196505-5B68C9FB-43CE-4E99-8A3D-55C0E70BA187 Q35252186-3F22FB26-FD04-450B-8ECB-B88FC0A088E0 Q35385971-97577E1B-548E-44A9-8B04-E744B7B85DB3 Q35408114-9763E780-87C6-4DD9-B6AF-1D2DD9A648C7

P2860

Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

http://www.wikidata.org/entity/Q37587740

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@en

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@nl

type

label

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@en

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@nl

prefLabel

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@en

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@nl

P1433

Q37587740-266EE7B9-909F-48B8-AA37-0CF1B7EB916A

P1476

Q37587740-9CC7E280-3EF9-463B-B274-4C528502C965

P2093

Q37587740-0C7E1284-EA98-4567-AF9B-F66FBE68883A

Q37587740-16EC4B95-73C5-418E-8286-52E4CE292110

Q37587740-17EF6F18-0A69-4589-ACE7-917E38A5AE38

Q37587740-1A5AB047-0F3F-4E78-824B-C209675C296C

Q37587740-4C45B0D2-2B72-4036-B24E-CB1A3690B7C0

Q37587740-74E0E61F-179F-4568-A356-0EE00FBF14EA

Q37587740-84C1935D-621F-4276-A180-D89FC33637CF

Q37587740-9E3288D0-063F-456A-890B-4802CED82777

Q37587740-A502DC29-2726-4033-825D-EBEBB1C9CF24

Q37587740-C87B4D3D-1A0D-4C1C-9B68-06683A201E84

P2860

Q37587740-05A6B97D-484F-4D03-A43B-6BE81208C660

Q37587740-0F4817AC-C5E9-4B58-886A-25B94805CAC6

Q37587740-1882F300-F231-496D-94E9-4BF8163FFF03

Q37587740-1BF57419-55F5-40D3-98DD-794E69618737

Q37587740-1CAFF617-DBEB-486E-8F1B-6249DA84C69B

Q37587740-2F2BB32C-BE56-4928-B72D-094DA1C39BEE

Q37587740-30D61529-AA46-45B7-8825-09253776EE5D

Q37587740-40DB293B-8322-4355-8C55-B09198740D29

Q37587740-42232242-572A-48D6-BBD8-AA1C5EBC02CE

Q37587740-45BA3D12-3BA7-4A57-B251-E29CB48692A3

P304

Q37587740-D59367D5-E90C-49AF-BA8B-4DEB90F2263E

P31

Q37587740-4D921E40-25B0-48AF-A6C4-67EE5073CE7A

P356

Q37587740-AA8395A6-0701-4903-AA08-AF9906691FFF

P407

Q37587740-7C3BF4CF-298E-4901-8614-F06AEAB1B774

P433

Q37587740-DFE92E64-F120-446A-885D-DA91E7219803

P478

Q37587740-DDCEF718-3C68-49C0-A53E-375CC55D7CAE

P50

Q37587740-3FFE86EF-6CE9-4A4F-8E85-136DBFA57481

Q37587740-47B5CFB3-D554-4FA9-8B72-D2E7D288ACA8

Q37587740-6ADE8E78-E6DC-42AC-BC23-6B08E8D57D91

Q37587740-8E72C1BF-F4ED-47EF-9BFF-71346A1DDB03

P577

Q37587740-9B3C55C6-E911-40A6-9A56-AA6CFA3B475E

P698

Q37587740-8F47FE48-A70B-470E-ACC0-0ACBEB2465AD

P921

Q37587740-4F31EB15-9B8D-4069-8455-3964D79CE005

Q37587740-D64422DF-8349-4FF8-BFCD-457AF7BB5C1B

P932

Q37587740-719FF5B2-9093-487D-A266-0B189CDAAC20

P356

PNAS.1318249111

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Persistent HIV-1 replication i ...... trations in lymphatic tissues.

@en

P2093

Ann Thorkelson

http://www.w3.org/2001/XMLSchema#string

Ashley T Haase

http://www.w3.org/2001/XMLSchema#string

Cavan Reilly

http://www.w3.org/2001/XMLSchema#string

Courtney V Fletcher

http://www.w3.org/2001/XMLSchema#string

Daniel C Douek

http://www.w3.org/2001/XMLSchema#string

Jodi Anderson

http://www.w3.org/2001/XMLSchema#string

Katherine Perkey

http://www.w3.org/2001/XMLSchema#string

Kathryn Staskus

http://www.w3.org/2001/XMLSchema#string

Mario Stevenson

http://www.w3.org/2001/XMLSchema#string

Meghan Rothenberger

http://www.w3.org/2001/XMLSchema#string

P2860

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

HIV infection and the risk of acute myocardial infarction.

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.

Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.

Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues.

Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

P304

2307-2312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1318249111

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Greg J. Beilman

Jeffrey G Chipman

Alan S. Perelson

Alexander Khoruts

P577

2014-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24469825

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3926074

http://www.w3.org/2001/XMLSchema#string